2023年为第11章备案的Sorrento治疗药物在2023年11月被清算,尽管收入低,库存波动大,但治疗方法仍在继续发展。 Sorrento Therapeutics filed for Chapter 11 in 2023, was liquidated in November, and continues developing therapies despite low earnings and high stock volatility.

Sorrento治疗学公司是一家设在圣地亚哥的生物制药公司,于2023年2月为第11章重组提出诉讼,并于2023年11月获准清算,标志着一项重大重组。 Sorrento Therapeutics, a San Diego-based biopharma company, filed for Chapter 11 reorganization in February 2023 and was approved for liquidation in November 2023, marking a major restructuring. 尽管收入高于同行,但报告的收益较低,交易价格较高. Despite higher revenue than peers, it reports lower earnings and trades at a premium valuation. 股票高度波动,贝塔为2.25,机构所有权微不足道,为0.00%。 The stock is highly volatile with a beta of 2.25, and institutional ownership is negligible at 0.0%. 该公司通过与马约诊所和智能药物治疗公司建立伙伴关系,继续发展癌症、慢性疼痛和传染病的治疗,包括CAR-T治疗和非类阿片止痛药物。 The company continues developing therapies for cancer, chronic pain, and infectious diseases, including CAR-T treatments and non-opioid pain drugs, through partnerships with Mayo Clinic and SmartPharm Therapeutics.